PL2215481T5 - Zastosowanie diagnostyczne indywidualnych postaci cząsteczkowych biomarkera - Google Patents

Zastosowanie diagnostyczne indywidualnych postaci cząsteczkowych biomarkera

Info

Publication number
PL2215481T5
PL2215481T5 PL08850368T PL08850368T PL2215481T5 PL 2215481 T5 PL2215481 T5 PL 2215481T5 PL 08850368 T PL08850368 T PL 08850368T PL 08850368 T PL08850368 T PL 08850368T PL 2215481 T5 PL2215481 T5 PL 2215481T5
Authority
PL
Poland
Prior art keywords
biomarker
diagnostic use
molecular forms
individual molecular
individual
Prior art date
Application number
PL08850368T
Other languages
English (en)
Other versions
PL2215481T3 (pl
Inventor
Lars Otto Uttenthal
Kristian Bangert
Original Assignee
Bioporto Diagnostics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40260606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2215481(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioporto Diagnostics As filed Critical Bioporto Diagnostics As
Publication of PL2215481T3 publication Critical patent/PL2215481T3/pl
Publication of PL2215481T5 publication Critical patent/PL2215481T5/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
PL08850368T 2007-11-15 2008-11-14 Zastosowanie diagnostyczne indywidualnych postaci cząsteczkowych biomarkera PL2215481T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98813707P 2007-11-15 2007-11-15
EP08850368.5A EP2215481B2 (en) 2007-11-15 2008-11-14 Diagnostic use of individual molecular forms of a biomarker
PCT/DK2008/050274 WO2009062520A1 (en) 2007-11-15 2008-11-14 Diagnostic use of individual molecular forms of a biomarker

Publications (2)

Publication Number Publication Date
PL2215481T3 PL2215481T3 (pl) 2014-08-29
PL2215481T5 true PL2215481T5 (pl) 2017-10-31

Family

ID=40260606

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08850368T PL2215481T5 (pl) 2007-11-15 2008-11-14 Zastosowanie diagnostyczne indywidualnych postaci cząsteczkowych biomarkera

Country Status (7)

Country Link
US (2) US20100304413A1 (pl)
EP (1) EP2215481B2 (pl)
JP (1) JP2011503587A (pl)
CN (1) CN101910845A (pl)
ES (1) ES2475990T5 (pl)
PL (1) PL2215481T5 (pl)
WO (1) WO2009062520A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227439B2 (en) 2008-05-15 2012-07-24 Morphotek, Inc. Treatment of metastatic tumors
WO2010054025A1 (en) 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use
EP2362943A1 (en) * 2008-11-21 2011-09-07 Phadia AB Methods, devices and kits for detecting or monitoring acute kidney injury
KR102003258B1 (ko) * 2009-12-20 2019-07-24 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
PT2531206T (pt) 2010-02-04 2017-09-05 Morphotek Inc Polipéptidos clorotoxina e conjugados e usos dos mesmos
JP2013532126A (ja) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PL2748605T4 (pl) * 2011-08-26 2019-08-30 Astute Medical, Inc. Sposoby i kompozycje do diagnozowania i prognozowania uszkodzenia nerek i niewydolności nerek
EP2788759B1 (en) 2011-12-08 2019-02-20 Astute Medical, Inc. Methods and uses for diagnosis of renal injury and renal failure
BR112015013515A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res métodos de geração de uma biblioteca de candidatos a fármaco definida por massa, e para identificar peptídeos possuindo uma propriedade farmacológica
TR201807542T4 (tr) 2013-01-17 2018-06-21 Astute Medical Inc Böbrek hasarı ve böbrek yetmezliği teşhisi ve prognozuna yönelik metotlar ve bileşimler.
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112018005175A2 (pt) 2015-09-17 2018-10-16 Amgen Inc predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23
WO2017214203A1 (en) 2016-06-06 2017-12-14 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
CN105974128A (zh) * 2016-06-12 2016-09-28 吉林大学 一种人中性粒细胞载脂蛋白同源二聚体的定量装置
WO2018145117A1 (en) 2017-02-06 2018-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11012774B2 (en) * 2018-10-29 2021-05-18 Apple Inc. Spatially biased sound pickup for binaural video recording
US11353446B2 (en) 2019-11-06 2022-06-07 Essenlix Corporation Methods and devices for correlating a biomarker in a non-blood bodily fluid with the biomarker in blood
US20220026426A1 (en) * 2020-07-23 2022-01-27 Fresenius Medical Care Holdings, Inc. System for determining peritonitis using homodimer neutrophil gelatinase-associated lipocalin

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635091A (en) * 1970-08-31 1972-01-18 Frederick D Linzer Midstream urine specimen and fractional fluid collectors
IT1074038B (it) * 1976-08-05 1985-04-17 Simes Esteri della epinina
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4357343A (en) * 1981-06-26 1982-11-02 Baxter Travenol Laboratories, Inc. Nutritional composition for management of renal failure
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
US5939272A (en) * 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
JP2912413B2 (ja) * 1990-03-28 1999-06-28 東亜医用電子株式会社 粒度分布作成方法
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
SE9401351D0 (sv) * 1994-04-21 1994-04-21 Venge A method for diagnosis
US5552313A (en) * 1994-11-21 1996-09-03 Kansas University DNA encoding mouse phosphotriesterase-related protein
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
US5821361A (en) * 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
AU8899298A (en) * 1997-08-06 1999-03-01 Zymogenetics Inc. Lipocalin homologs
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
AU5330200A (en) * 1999-06-18 2001-01-09 Michigan State University Method and apparatus for the detection of volatile products in a sample
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
AU2001293964B2 (en) * 2000-10-03 2007-06-14 Rowett Research Institute Method of assaying pyrrole-containing biological compounds
JP2004528814A (ja) * 2000-10-13 2004-09-24 チルドレンズ メディカル センター コーポレーション 組織再構築関連状態についての非侵襲性酵素スクリーニング
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
DE60233301D1 (de) * 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
US6847451B2 (en) * 2002-05-01 2005-01-25 Lifescan, Inc. Apparatuses and methods for analyte concentration determination
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2360475B1 (en) * 2003-03-27 2019-10-02 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CN101163971B (zh) * 2004-12-20 2013-03-20 免疫体公司 测定作为肾病诊断标记物的嗜中性粒细胞明胶酶相关性脂笼蛋白
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
AU2007217861A1 (en) * 2006-02-17 2007-08-30 Children's Medical Center Corporation Free NGAL as a biomarker for cancer
US20080061149A1 (en) * 2006-09-11 2008-03-13 Colin Tanner Proximity payment card with security interlock
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
JP5848006B2 (ja) † 2007-10-19 2016-01-27 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Ｎｇａｌの検出用イムノアッセイ及びキット
US20090269777A1 (en) * 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090123970A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof

Also Published As

Publication number Publication date
CN101910845A (zh) 2010-12-08
WO2009062520A1 (en) 2009-05-22
EP2215481B1 (en) 2014-04-02
EP2215481A1 (en) 2010-08-11
EP2215481B2 (en) 2017-01-18
JP2011503587A (ja) 2011-01-27
US20130177923A1 (en) 2013-07-11
ES2475990T5 (es) 2017-07-06
PL2215481T3 (pl) 2014-08-29
US20100304413A1 (en) 2010-12-02
ES2475990T3 (es) 2014-07-11

Similar Documents

Publication Publication Date Title
PL2215481T5 (pl) Zastosowanie diagnostyczne indywidualnych postaci cząsteczkowych biomarkera
EP2155058A4 (en) INDICATOR
TWI370413B (en) Graphical indicator
GB2461448B (en) Transducer
IL202451A0 (en) High-sensitvity pressure-sensing probe
GB0716672D0 (en) Laryngoscope
PL2208085T3 (pl) Pomiar oparty na funkcji szczegółowej
AU310642S (en) Diagnostic meter
AU312219S (en) Diagnostic meter
GB0700677D0 (en) Probe
GB0716202D0 (en) Improved fluid probe
EP2324353A4 (en) TRANSDUCER MICROARRAY FUNCTIONALIZED SELECTIVELY
IL199807A0 (en) Biometric diagnosis
EP1987846A4 (en) DIAGNOSTIC MARKER
EP2239543A4 (en) INSTRUMENT OF INDICATION
GB2458124B (en) Indicator
GB0823616D0 (en) Instrument
GB0708411D0 (en) Lanthanide probes
GB0701401D0 (en) Indicator
GB2448742B (en) Indicator
TWI339731B (en) Probe assembly
HU0700126V0 (en) Self-alertness tester
PL117136U1 (pl) Twardościomierz
HK1102894A2 (en) Electrontherapy instrument
GB0809376D0 (en) Diagnostic marker